7. (Amended) A method of increasing sexual desire, interest or performance in a human who is desirous thereof which comprises administering a sexually useful effective amount of a compound of the formula (A)



where

R_1, R_2 and R_3 are the same or different and are:

-H,

C_1-C_6 alkyl,

C_3-C_5 alkenyl,

C_3-C_5 alkynyl,

C_3-C_5 cycloalkyl,

C_4-C_{10} cycloalkyl,

phenyl substituted C_1-C_6 alkyl,

-NR_1R_2 where R_1 and R_2 are cyclized with the attached nitrogen atom to produce pyrrolidiyl, piperidinyl, morphoninyl, 4-methyl piperazinyl or imidazolyl;

X is:

-H,

C_1-C_6 alkyl,

-F, -Cl, -Br, -I,

-OH,

C_1-C_6 alkoxy,

cyano,

carboxamide,

carboxyl,

(C_1-C_6 alkoxy)carbonyl,

A is:

CH,

CH_2,

CH-(halogen) where halogen is -F, -Cl, -Br, -I,

$CHCH_3$,

C=O,

C=S,

$C\text{-}SCH_3$,

C=NH,

$C\text{-}NH_2$,

$C\text{-}NHCH_3$,

$C\text{-}NHCOOCH_3$,

C-NHCN,

SO_2,

N;

B is:

CH_2,

CH,

CH-(halogen) where halogen is as defined above,

C=O,

N,

NH,

$N\text{-}CH_3$,

D is:

CH,

CH_2,

CH-(halogen) where halogen is as defined above,

C=O,

O,

N,

NH,

$N\text{-}CH_3$;

and n is 0 or 1, and where ⎓ is a single or double bond, with the provisos:

(1) that when n is 0, and

A is CH_2, CH-(halogen) where halogen is as defined above, $CHCH_3$, C=O, C=S, C=NH, SO_2;

then D is CH_2, CH-(halogen) where halogen is as defined above, C=O, O, NH, N-CH_3;

(2) that when n is 0, and

A is CH, C-SCH_3, C-NH_2, C-$NHCH_3$, C-$NHCOOCH_3$, C-NHCN, N; then

D is CH, N;

(3) that when n is 1, and

A is CH_2, CH-(halogen) where halogen is as defined above, $CHCH_3$, C=O, C=S, C=NH, SO_2; and

B is CH_2, CH-(halogen) where halogen is as defined above, C=O, NH, N-CH_3; then

D is CH_2, C=O, O, NH, N-CH_3;

(4) that when n is 1, and

A is CH, C-SCH_3, C-NH_2, C-$NHCH_3$, C-$NHCOOCH_3$, C-NHCN, N; and

B is CH, N; then

D is CH_2, C=O, O, NH, N-CH_3;

(5) that when n is 1, and

A is CH_2, $CHCH_3$, C=O, C=S, C=NH, SO_2, and

B is CH, N; then

D is CH, N; or a pharmaceutically acceptable salt thereof to the human.

11. (New) The method according to claim 7 where the human is a male.

12. (New) The method according to claim 7 where the human is a female.

13. (New) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt thereof is administered orally, intra-nasally, buccally, intra-pulmonary, parenterally, or rectally.

14. (New) The method according to claim 13 where the compound of formula (A) or pharmaceutically acceptable salt thereof is administered orally, intra-nasally, buccally, or intra-pulmonary.

15. (New) The method according to claim 14 where the compound of formula (A) or pharmaceutically acceptable salt thereof is administered orally.

16. (New) The method according to claim 7 where the sexually useful effective amount is from about 0.2 thru about 8 mg/person/dose.

17. (New) The method according to claim 16 where the sexually useful effective amount is from about 0.5 thru about 5 mg/person/dose.

18. (New) The method according to claim 17 where the sexually useful effective amount is from about 1 thru about 3 mg/person/dose.

19. (New) The method according to claim 7 where the compound of formula (A) is (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one.

20. (New) The method according to claim 19 where the pharmaceutically acceptable salt of the compound is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Z)-2-butenedioate (1:1).

Q2 Cont

21. (New) The method according to claim 7 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, CH_3-$(CH_2)_n$-COOH where n is 0 thru 4, and HOOC-$(CH_2)_N$-COOH where n is as defined above.

22. (New) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt is administered from about 10 minutes to about 8 hr prior to sexual activity.

23. (New) The method according to claim 22 where the compound of formula (A) pharmaceutically acceptable salt is administered from about 0.5 hr to about 1 hr prior to sexual activity.

24. (New) The method according to claim 23 where the compound of formula (A) pharmaceutically acceptable salt is administered about 0.5 hr prior to sexual activity.

25. (New) The method according to claim 7 where the human does not have Parkinson's disease.

26. (New) The method according to claim 7 where the human does not experience postural hypotension.

27. (New) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt is used in combination with a sexually effective amount of one or more vascular smooth muscle relaxation agents where the compound of formula (A) or pharmaceutically acceptable salt is administered within 8 hours prior to sexual activity and where the vascular smooth muscle relaxation agent is administered to the human within a sexually effective time period prior to sexual activity.

28. (New) The method according to claim 27 where the vascular smooth muscle relaxation agent is selected from the group consisting of phosphodiesterase type 5 inhibitors, phosphodiesterase type 3 inhibitors, non-selective phosphodiesterase inhibitors, nitric oxide donor drugs, alpha type 1 adrenergic receptor antagonists, alpha type 2 adrenergic receptor antagonists, prostaglandin E1 receptor agonists (PGE1), and vasoactive intestinal polypeptide (VIP) agents.

29. (New) The method according to claim 28 where the vascular smooth muscle relaxation agent is selected from the group consisting of sildenafil, ICOS-351, milrinone, papaverine, linsidomine, phentolamine, yohimbine, prostaglandin E1 (PGE1), and VIP.

30. (New) The method according to claim 8 where the pharmaceutically acceptable salt of the compound is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione malate.

STATUS OF CLAIMS

Claims 1-10 are pending in the application before the entry of this amendment.

Claim 7 is being amended and claims 11-30 are being amended by this amendment.

Claims 1-30 are pending after the entry of this amendment.

REMARKS

In the Office communication date mailed 07/02/2002 the Examiner issued a restriction and an election requirement. In reply to the restriction requirement the Applicants elect Group IV, which includes claims 7 and 8 and new claims 11- 30. In reply to the election requirement the Applicants provisionally elect the compound (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-

2(1H)-thione, which is the compound of EXAMPLE 8, the claims readable thereon being claims 7 and 8 and new claims 11-18 and 21-30.

Respectfully submitted,

Date: 7/26/02

Austin W. Zhang, Attorney
Registration No. 48,061

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-8813 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316